^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IK-930

    i
    Other names: IK-930
    Company:
    Ikena Oncology
    Drug class:
    TEAD1 inhibitor
    Related drugs:
    18d
    Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=198, Recruiting, Ikena Oncology | Trial completion date: Oct 2024 --> Jun 2025 | Trial primary completion date: Oct 2024 --> Jun 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    YAP1 (Yes associated protein 1) • TFE3 • CAMTA1 (Calmodulin Binding Transcription Activator 1) • TAFAZZIN (Tafazzin)
    |
    TFE3 fusion
    |
    Tagrisso (osimertinib) • IK-930
    1year
    TY-0584: A potent, orally available small molecule YAP/TEAD inhibitor, exhibits anti-tumor effects in vitro and in vivo (AACR 2023)
    Therefore, small molecules that target palmitoylation of TEAD have been explored and VT3989 (NCT04665206) and IK-930 (NCT05228015) have success to enter the clinical trials...In line with the results of the in-vitro experiments, another YAP/TEAD inhibitor TY-0536 in combination with TY-9591 significantly delay the tumor regrowth in the PC9 CDX mouse model...[Shengli Dong and Apeng Liang contributed equally to this work. Jun Li, Shengli Dong, and Apeng Liang are the corresponding authors.]
    Preclinical
    |
    NF2 (Neurofibromin 2)
    |
    NF2 deletion
    |
    IK-930 • TY-0584 • VT3989 • TY-9591
    2years
    Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=158, Recruiting, Ikena Oncology
    New P1 trial
    |
    YAP1 (Yes associated protein 1) • TFE3
    |
    TFE3 fusion
    |
    IK-930